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Abstract
Human stem cells are scalable cell populations capable 
of cellular differentiation. This makes them a very at-
tractive in vitro  cellular resource and in theory provides 
unlimited amounts of primary cells. Such an approach 
has the potential to improve our understanding of hu-
man biology and treating disease. In the future it may 
be possible to deploy novel stem cell-based approaches 
to treat human liver diseases. In recent years, efficient 
hepatic differentiation from human stem cells has been 
achieved by several research groups including our own. 
In this review we provide an overview of the field and 
discuss the future potential and limitations of stem cell 
technology.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
End stage liver disease (ESLD) is an irreversible condi-
tion that leads to the eventual failure of  the liver. It may 
be the final stage of  many liver diseases, for example, 
viral hepatitis, autoimmune hepatic disorders, fatty liver 
disease, drug induced liver injury, and hepatocellular car-
cinoma, with extremely poor prognosis. The incidence 
of  ESLD is increasing worldwide[1], and current optimal 
treatment for ESLD is orthotopic liver transplantation[2]. 
However limited availability of  donor livers and immu-
nological incompatibilities are two major obstacles to its 
routine deployment[3]. This highlights the important need 
for alternative therapeutic strategies. Researchers have 
proposed that stem cell biology could provide a scalable 
answer for the treatment of  ESLD, providing cells for 
transplant and/or cell sources for studying liver disorders 
and identifying novel treatments. 
Cell-based therapy requires the use of  cells to replace 
or facilitate the repair of  damaged tissue. Candidate 
cells for this approach include bipotential, multipotent, 
pluripotent cells, and primary hepatocytes. Pluripotent 
stem cells (PSCs), including human embryonic stem cells 
(hESCs) and induced pluripotent stem cells (iPSCs), pos-
sess the ability to self  renew and differentiate into all 
somatic cells, offering unlimited potential and are not 
restricted by donor tissue supply.
hESCs are derived from the inner cell mass of  the 
human blastocyst, and can differentiate into all three pri-
mary germ layers[4]. Human iPSCs are produced by forced 
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expression of  specific stem cell genes[5]. In recent years, 
researchers have developed robust procedures to generate 
functional hepatocyte-like cells (HLCs) from both PSC 
populations[6-8]. However, it is notable that PSC strategies 
have not yielded, as yet, a cell type that appropriately con-
tributes to tissue homeostasis as cell transplantation fre-
quently results in tumour formation[9,10]. As a result, scal-
able cell-based therapies from PSCs are likely to be longer-
term strategies which require significant refinement. 
Extra-corporeal support has been proposed as a mid-
term strategy, in particular bio-artificial livers, to treat hu-
man liver disease. Bio-artificial livers (BALs) are designed 
to filter and biotransform toxic substances, and have 
been used successfully to bridge patients to transplant or 
treat acute liver failure. Research demonstrates that BALs 
can reduce mortality in acute liver failure compared with 
traditional standard medical therapy[11,12], but the applica-
tion has been severely limited by the poor availability of  
functional human hepatocytes. By employing PSC tech-
nology, it may now be possible to produce humanised 
BAL devices at reasonable cost.
In addition to their important role in the clinic, hu-
man hepatocytes have a critical part to play in the drug 
discovery process. Many candidate compounds fail at 
late stage or even after approval due to unanticipated 
toxicity. In routine drug discovery, the pharmaceutical 
industry deploys the tumor-derived cells and primary he-
patocytes to screen compounds. While these models are 
useful, they do not always extrapolate to human biology 
and exhibit poor lifespan and variable metabolic activity. 
PSCs-derived hepatocytes have the potential to overcome 
these problems. Advances in stem cell biology and repro-
graming have allowed the development of  novel models 
which have the potential to provide another level of  un-
derstanding behind the pathophysiology of  liver diseases. 
iPSC modelling also provides us with potential system to 
better understand the influence of  gene polymorphisms. 
Human PSCs derived HLCs show great promise for 
research and clinical applications including cell-based 
therapies, drug development, and disease modeling. This 
review gives an overview of  human hepatic differentia-
tion from PSCs and their potential application in modern 
medicine. 
CURRENT CELL SOURCES USED IN 
HEPATOLOGY
Primary human hepatocytes and liver cancer cell lines 
Hepatocytes are the principle cell type found in the liver 
and perform the majority of  the liver functions. Primary 
human hepatocytes (PHHs) are therefore a useful tool 
for medical applications such as cell-based therapy and 
drug discovery. However, PHHs are mainly obtained 
from scarce and low quality resected surgical speci-
mens[13]. The scarcity and variability in these preparations 
restricts their widespread application in vitro[14]. Therefore 
liver cell lines have been employed routinely as they dem-
onstrate long lifespan and are easy to maintain. HepG2 
is a liver cell line derived from fetal tissue which exhibits 
poor metabolic function and secrete a variety of  soluble 
serum proteins[15]. They have been used as a model sys-
tem for cytochrome P450 (CYP) metabolism and toxic-
ity. And additionally they have been used in clinical trials 
with bioartificial liver devices[16,17]. Interestingly, a clonal 
derivative of  the HepG2 line, C3A, demonstrates marked 
reduction in α-fetoprotein (AFP) and increased albumin 
(ALB) secretion, indicating a more mature status in vitro. 
More recently, a new human hepatoma cell line has been 
derived. HepaRG demonstrates a number of  liver-specif-
ic functions including the expression of  CYP 1A2, 2B6, 
2C9, 2E1, 3A4[18,19] and better overall performance than 
existing liver cell lines. Although informative and scal-
able, liver cancer cell lines show lower drug-metabolizing 
activity than their adult counterparts and do not accu-
rately predict human drug toxicity[20] and therefore do not 
constitute a real alternative to the gold standard primary 
hepatocyte. Moreover, such cells may provide interesting 
in vitro models or the bio-component of  the BAL, but 
they could not be used for cell transplantation in vivo.
Oval cells and hepatoblasts 
Oval cells are an adult liver cell population that emerges 
from the biliary tree following chronic liver injury. Several 
studies have investigated the transplantation of  oval cells 
showing that these bipotential cells could proliferate and 
contribute to both parenchyma and biliary epithelia in 
vivo[21-28]. Oval cells express the stem cell markers Thy-1 
(CD90), CD34 and Sca-1, along with liver-specific mark-
ers, including AFP, Gamma-glutamyltransferase, laminin 
and cytokeratin 19 (CK 19)[23,24]. 
The tissue microenvironment plays an essential role 
in orchestrating oval cell-mediated liver regeneration. 
Laminin contributes to the maintenance of  undifferenti-
ated progenitor cells and progenitor cell-mediated tissue 
repair[29]. Moreover, Kallis et al[30] demonstrated that ex-
tracellular matrix (ECM) remodelling during resolution 
and laminin deposition was likely to be important pre-
requisite to hepatic progenitor cell activation, expansion 
and repair. 
Similar to oval cells, hepatoblasts from fetal liver 
could also represent a potential source of  hepatocytes 
and biliary epithelial cells[24,31]. The bipotential nature of  
this cell type also makes it an attractive target for therapy. 
Transplant studies demonstrate that hepatoblasts may be 
a potential therapeutic strategy for ESLDs or hepatic fail-
ure. Although great progress in the fundamental research 
and clinical application have been made, there are still 
limitations to widespread use of  these cells, such as low 
cell number in vivo, no specific biomarker for purification 
and poor expansion in vitro. 
Bone marrow stem cells and mesenchymal stem cell 
The bone marrow (BM) contains stem cells populations 
in vivo. They can be roughly divided into of  hematopoietic 
(HSCs) and nonhematopoietic stem cells usually referred 
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to as mesenchymal stem cells (MSCs). The great success 
of  BM stem cell for treatment of  leukaemia has attracted 
scientists to use these cells for other serious diseases such 
as ESLD. Analysis of  BM transplant into mouse models 
and patients have demonstrated that transplanted BM 
could contribute to partial correction of  hepatic func-
tion[32-34]. However, the role of  BM is controversial; some 
researchers found that BM didn’t contribute to hepato-
cyte or biliary cell differentiation and liver regeneration, 
but actually contributed to liver fibrosis[35,36], which raises 
serious safety concerns. 
Similar to BM, MSCs have been successfully trans-
planted[37]. They are multipotent stem cells capable of  
mesodermal, neuro-ectodermal and endodermal dif-
ferentiation depending on surrounding microenviro-
ment[38-41]. In addition, MSCs have anti-fibrotic proper-
ties inhibiting activated fibrogenic cells such as hepatic 
stellate cells[42]. The role of  MSCs in liver regeneration 
and disease has been evidenced in animal models. More-
over MSC based therapies for patients with ESLDs have 
shown promise in phase Ⅰ and Ⅱ clinical trials[37,43,44]. 
Treatment was well tolerated by all patients with liver 
fibrosis and heptic function improved following MSCs 
transplantation[37] and during the follow-up[43]. Peng et al[45] 
reported that the biochemical hepatic index and MELD 
score were markedly improved from 2-3 wk post trans-
plantation. However, long-term hepatic function were 
not significantly enhanced in 527 patients with liver fail-
ure caused by hepatitis B. Although MSC transplantation 
confers benefit to patients with liver cirrhosis, it may not 
be applicable to all kind of  ESLDs. 
HEPATIC DIFFERENTIATION FROM 
PLURIPOTENT STEM CELLS
Human ESCs are derived from the inner cell mass of  blas-
tocyst stage embryos and are highly primitive cells which 
exhibit pluripotency and the ability to self-renew[4,46]. Ram-
bhatla et al[47] reported the directed differentiation of  hu-
man ESCs to HLCs for the first time in 2003, which could 
express some hepatocyte markers. Since then labs have 
established more robust and efficient procedures to derive 
better functioning HLCs. Embryoid body (EB) formation 
has been one method to differentiate ESCs into hepato-
cytes. However, this approach exhibits limitations to scale 
and culture definition. Therefore, monolayer adherent 
culture systems have been developed to direct ESC he-
patic differentiation into hepatocytes, which bypass these 
limitations[6,48-51]. We developed a simple 3-stage procedure 
by which hESCs can be directly differentiated to HLCs at 
an efficiency of  about 90%[6,8]. Our research demonstrated 
that Wnt3a signaling was important in this process, im-
proving hepatocellular function both in vitro and in vivo[6,52]. 
Most recently we identified a novel polyurethane extra 
cellular support which delivers long-term and stable HLC 
function which is drug inducible[53]. 
In 2006, it was demonstrated that murine fibroblasts 
could be reprogrammed into a pluripotent state similar to 
that observed in ESCs[54]. Subsequently Takahashi et al[5] 
and Park et al[55] successfully reprogrammed human so-
matic cells into iPSCs.  They generated PSCs from human 
skin through ectopic expression of  four genes (Oct3/4, 
Sox2, c-Myc, and Klf4), which were known to be involved 
in the induction of  murine pluripotency. Since these ex-
periments researchers continue to refine and simplify the 
reprogramming process.
Human iPSCs and ESCs display similar morphologies, 
proliferation rates and expression of  a number of  stem 
cell biomarkers. However, specific differences between 
ESCs and iPSCs exist. Obviously the biggest difference 
is that iPSCs are derived from adult tissues. In addition, 
some comparative genomic analyses shows that hundreds 
of  genes are differentially expressed in these two cell 
types[56]. Given their adult origin, iPSCs can contain an 
epigenetic “memory” of  the donor tissue[57,58], which can 
restrict their differentiation potential and therefore utility. 
iPSCs have been differentiated to numerous cell 
types[59], including hepatocytes. We and others have devised 
efficient methods to generate hepatocytes in vitro[7,60,61]. The 
derivative HLCs from both hESC and iPSC models dem-
onstrate a similar expression of  genes important for nor-
mal liver physiology. Jozefczuk et al[62] demonstrated 80% 
similarity of  gene expression between HLCs derived from 
hESCs or iPSCs. Additionally, there were specific differ-
ences between the types of  HLCs derived from ESCs and 
iPSCs in particular the CYP genes.
Most recently a study reported the direct conversion 
of  murine fibroblasts to HLCs without the need for cel-
lular pluripotency. In two studies HLC differentiation 
was conferred using either Gata4, Hnf1α and Foxa3, or 
HNF4a in combination with Foxa1, Foxa2 or Foxa3[63,64]. 
HLCs exhibited hepatic gene expression and function in 
vitro and rescued fumarylacetoacetate-hydrolase-deficient 
(Fah-/-) mice in vivo[63,64]. These studies provide another 
alternative method of  hepatic conversion, which offer 
potential for liver research and therapy.
HEPATIC DIFFERENTIATION IN 
CELL-BASED THERAPIES AND TOOLS
Hepatic differentiation for cell-based therapy 
PSCs offer a possible source to treat liver disease. Cell 
therapy for liver disease includes transplantation (including 
genome edited cells to correct metabolic defects[65]) and 
bio-artificial liver devices. The cell-based approaches are 
very encouraging, but further studies are required to dem-
onstrate long-term safety of  cell-based transplantation[9,10]. 
In the interim BALs containing hepatocytes could provide 
alternative support for patients with acute hepatic failure 
or awaiting liver transplantation. Efforts to generate long-
lived functional HLCs may allow the development of  
more highly effective BALs. The potential application of  
human stem cells in cell-based therapy for liver diseases is 
summarised in Figure 1. 
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have provided models that may overcome some of  the 
problems associated with existing technology. Moreover, 
in parallel with extracorporeal device development, stem-
cell-derived HLCs in three dimensional (3D) are more 
likely to mimic human liver properties in vitro. 
Hepatic differentiation for disease modelling
PSCs have provided scientists with novel models to study 
human liver disease. Rashid et al[60] reported an effective 
procedure for hepatocyte generation from iPSCs exhibit-
ing disease mutations. Using these cells, they modeled 
inherited metabolic disorders that affect the liver; alpha1-
antitrypsin deficiency, familial hypercholesterolemia, and 
glycogen storage disease type 1a. These models accurately 
reflected elements of  the disease process. More recently 
research iPSCs, obtained from patients with tyrosinemia, 
glycogen storage disease, progressive familial hereditary 
cholestasis, and Crigler-Najjar syndrome, were differenti-
ated into functioning HLCs[68]. These inherited liver dis-
eases that mainly arise as a result of  loss of  function mu-
tation, therefore these studies offers a unique opportunity 
to study the effects of  specific gene defects on human 
liver biology and to better understand liver pathogenesis 
in disease. 
Improving hepatic differentiation
PSC technologies have the potential to produce unlimited 
amounts of  human liver cells. As discussed above, human 
hepatocytes from PSCs could be utilized for cell-based 
therapy, assessment of  drug toxicity and disease model-
ling. Therefore, the PSC-derived HLCs should be reliable, 
stable in character and display high levels of  metabolic 
activity. A better understanding of  human liver develop-
ment and optimal tissue microenvironments are likely to 
play an important role in this process. 
HUMAN LIVER DEVELOPMENT
Liver development occurs through a series of  reciprocal 
tissue interactions between the embryonic endoderm and 
Hepatic differentiation for drug discovery 
The drug development process is a hugely expensive 
process, due to its length and high levels of  compound 
attrition. Drug development proceeds through several 
stages in order to produce a drug that is safe, efficacious, 
and meets regulatory requirements (Figure 2). The liver 
plays a central role in the metabolism of  a majority of  
drugs. Therefore, a standardized screening model with 
human hepatocytes for new drug compounds could help 
to reduce drug attrition and costs. Traditional cell models 
for drug discovery include primary human hepatocytes, 
immortalised cell lines and animal tissues; however, these 
cell sources possess a number of  limitations including 
poor function, species variability and instability in cul-
ture[14,20]. Advances in PSCs research and liver engineering 
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or bio-artificial liver construction.
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nearby mesoderm. Endoderm contributes to the digestive 
tract and has a principal role in the development of  the 
liver (Figure 3). The secretions of  fibroblast growth factor 
(FGF) and bone morphogenetic protein (BMP) from the 
cardiac mesoderm and septum transversum mesenchyme 
(STM) help orchestrate human liver development from 
foregut endoderm in concert[69] with canonical Wnt signal-
ling[6,70,71]. Three to 4 wk post fertilisation cells called hepa-
toblasts, positive for CK19 and HepPar1, are detected for 
the first time[31]. The hepatoblasts proliferate and form the 
liver bud. The hepatic endoderm thickens into a columnar 
epithelium, and hepatoblasts delaminate and invade the 
STM and undergo cellular proliferation and differentia-
tion. Experiments have shown that a number of  factors 
such as FGF, epidermal growth factor (EGF), hepato-
cyte growth factor (HGF), transforming growth factor 
(TGF), tumor necrosis factors (TNF), and interleukin-6 
contribute to the hepatocytes proliferation and differen-
tiation[72,73]. Between 6-8 wk gestation, the bile duct and 
hepatic structure are easily identified[31]. Maturation of  
hepatocytes and bile epithelial cells continues after birth. 
An overview of  embryonic liver development is summa-
rized in Figure 3. 
IMPROVING CELL CULTURE 
MICROENVIRONMENT
The tissue microenvironment also plays an essential role 
in liver development and hepatic differentiation. Two 
dimensional (2D) hepatic differentiation is probably 
the most widely used system in laboratories. While this 
technology is efficient and scalable, there are several 
drawbacks related to 2D culture, including poor drug in-
ducibility and rapid cell dedifferentiation. During human 
liver development, hepatocytes mature in a 3D environ-
ment with a number of  cell types providing support. 
Figure 3  Human fetal liver development[31,74]. The key stages of human liver development are shown in pink and blue. Endoderm formation occurs in the 2nd-3rd 
wk of fetal development. The liver bud forms between week 3-4 and expands rapidly. Hepatocytes and biliary epithelia differentiate and mature from 7 wk post fertilisa-
tion and this process continues in the neo-nate.
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In light of  the increasing need for better-differentiated 
hepatocytes from PSCs, we and others have developed 
3D systems to improve and stabilize hepato-cellular phe-
notype[53,75,76]. 
Undoubtedly 3D culture leads to improvements in 
hepatic function. In the future modulation of  oxygen-
ation and physiological delivery of  nutrients in 3D envi-
ronment have great potential to improve cell phenotype 
and therefore utility.
CONCLUSION
The development of  hESC and iPSC technology has led 
to a new era of  discovery in liver medicine. Advances 
in PSC technology offer the promise of  scalable human 
hepatocytes for cell-based therapies, assessment of  drug 
efficacy and toxicity, and disease modelling. The chal-
lenge remains to cost effectively scale up this technology 
for industrial manufacture. A better knowledge of  liver 
development and the use of  novel supportive culture sys-
tems will help to improve the manner in which we derive 
mature human hepatocytes.
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